COMP <GO>
RVTY vs ABBV // 10Y YIELD & FRED MACRO BETA
Revvity Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RVTY 3
— ABBV 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ABBV
LAST: $157.00 (-5.30%) • MKT CAP: $18.50B
macro-sensitivity
0.95
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVTY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVTY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.10% | 29.00% | -25.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 48.2x | 33.3x | +14.90 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 2.75% | 3.47% | -0.72 | ABBV | /fcf-yield <GO> |
| Operating Margin | 12.50% | 24.60% | -12.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 6.90% | +1.50 | RVTY | /net-margins <GO> |
| Revenue Growth (YoY) | 3.70% | 8.60% | -4.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.18% | 2.27% | -2.09 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.37 | 5.33 | -1.96 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | RVTY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 72.8 | -17.68 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.95 | 1.15 | -0.20 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 71.3x | 113.1x | -41.80 | RVTY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.50B | $513.86B | -$495.36B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVTY REV | ABBV REV | RVTY GROSS % | ABBV GROSS % | RVTY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $61.16B | 44.0% | 70.2% | $509.4M | $17.82B |
| FY 2024 | $2.76B | $56.33B | 44.0% | 70.0% | $541.7M | $17.83B |
| FY 2023 | $2.75B | $54.32B | 44.0% | 44.0% | -$32.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVTY // BETA 0.95
ABBV // BETA 1.15